UMH Properties, Inc. (UMH)’s director Kenneth Quigley Buys 82 shares of the Company; Last Week Acorda Therapeutics, Inc. (ACOR) Analysts

The director of Umh Properties Inc and firm’s insider Kenneth Quigley paid for 82 shares of the New Jersey-based company based on the avg. market share price which is $12.3 for each one share. The shares are worth based on the market roughly $1,005 U.S Dollars. This is not his first insider trade, in the last 30 days, he acquired another 86 shares worth $1,000 USD. The purchased shares were purchased on March 19, 2018 and the document that contains the source information, filed with the SEC can be found here. Kenneth Quigley now holds 4,824 shares or 0.01% of Umh Properties Inc’s market cap.

Among 14 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Acorda Therapeutics had 43 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was maintained by Leerink Swann on Tuesday, August 29 with “Hold”. The firm has “Perform” rating given on Wednesday, January 31 by Oppenheimer. As per Tuesday, October 31, the company rating was maintained by Cantor Fitzgerald. On Wednesday, November 15 the stock rating was maintained by Cowen & Co with “Buy”. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, November 16. On Wednesday, January 31 the stock rating was maintained by Janney Capital with “Hold”. The company was maintained on Monday, November 20 by H.C. Wainwright. On Tuesday, September 1 the stock rating was initiated by Raymond James with “Market Perform”. Stifel Nicolaus maintained Acorda Therapeutics, Inc. (NASDAQ:ACOR) rating on Tuesday, October 31. Stifel Nicolaus has “Buy” rating and $26.0 target. J.P. Morgan maintained Acorda Therapeutics, Inc. (NASDAQ:ACOR) rating on Tuesday, June 6. J.P. Morgan has “Hold” rating and $2400 target. See Acorda Therapeutics, Inc. (NASDAQ:ACOR) latest ratings:

15/02/2018 Broker: Piper Jaffray Rating: Buy Upgrade
07/02/2018 Broker: Goldman Sachs Rating: Hold Upgrade
31/01/2018 Broker: Janney Capital Rating: Hold Maintain
31/01/2018 Broker: Oppenheimer Old Rating: Perform New Rating: Perform Old Target: $18 New Target: $21 Maintain
17/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $31.0 Maintain
14/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $34.0 Maintain
28/11/2017 Broker: Piper Jaffray Rating: Hold New Target: $22.0 Initiate
20/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $34.0 Maintain
15/11/2017 Broker: Cowen & Co Rating: Buy New Target: $30.0 Maintain
15/11/2017 Broker: Jefferies Rating: Hold New Target: $25.0 Maintain

Since October 9, 2017, it had 0 buys, and 3 sales for $1.81 million activity. 34,520 shares valued at $952,319 were sold by Wasman Jane on Friday, January 19. LAWRENCE DAVID also sold $854,911 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) shares.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company has market cap of $1.15 billion. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It currently has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.23, from 1.22 in 2017Q2. It dropped, as 19 investors sold Acorda Therapeutics, Inc. shares while 39 reduced holdings. 22 funds opened positions while 49 raised stakes. 51.31 million shares or 4.56% more from 49.07 million shares in 2017Q2 were reported. The California-based Partner Invest Ltd Partnership has invested 1.34% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Gsa Cap Ptnrs Limited Liability Partnership holds 22,862 shares or 0.04% of its portfolio. Dekabank Deutsche Girozentrale accumulated 23,400 shares or 0% of the stock. Moreover, Tower Rech Cap Ltd Liability (Trc) has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 1,058 shares. Wells Fargo Com Mn has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 85,357 shares. Riverhead Cap Mgmt Limited Liability Company owns 3,687 shares. Ls Invest Limited Liability invested in 0% or 1,767 shares. 9,299 were accumulated by Two Sigma Limited Co. Sg Americas Limited Liability Company, a New York-based fund reported 4,806 shares. Gotham Asset Mgmt Lc has 153,742 shares. 312,239 were reported by Ameriprise Fincl. D E Shaw & Co Inc holds 0.02% or 563,913 shares. Alps Advsr invested 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Swiss Fincl Bank owns 76,200 shares. 69,271 are held by California State Teachers Retirement.

The stock decreased 2.60% or $0.65 during the last trading session, reaching $24.4. About 156,635 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 40.68% since March 19, 2017 and is downtrending. It has underperformed by 57.38% the S&P500.

Investors sentiment decreased to 1.71 in Q3 2017. Its down 0.66, from 2.37 in 2017Q2. It dived, as 9 investors sold UMH Properties, Inc. shares while 21 reduced holdings. 24 funds opened positions while 47 raised stakes. 19.06 million shares or 4.77% more from 18.19 million shares in 2017Q2 were reported. Northern Trust Corporation has invested 0% of its portfolio in UMH Properties, Inc. (NYSE:UMH). Parametric Port Assoc Limited Liability Corp owns 63,469 shares or 0% of their US portfolio. Connors Investor Serv invested in 16,213 shares. Raymond James & Associate has 26,519 shares. Martingale Asset Mgmt L P has 130,713 shares. Moreover, Deutsche Comml Bank Ag has 0% invested in UMH Properties, Inc. (NYSE:UMH). Palisade Cap Management Lc Nj, New Jersey-based fund reported 92,925 shares. Wells Fargo & Mn accumulated 1.07 million shares. Nationwide Fund Advisors reported 51,673 shares or 0% of all its holdings. Wellington Mgmt Gru Llp stated it has 371,282 shares or 0% of all its holdings. Loeb Partners invested in 0.55% or 115,616 shares. Daiwa Secs Group Inc has 0% invested in UMH Properties, Inc. (NYSE:UMH) for 3,100 shares. Dimensional Fund Advsrs L P invested in 387,438 shares or 0% of the stock. Howe & Rusling Inc stated it has 0% in UMH Properties, Inc. (NYSE:UMH). Tower Rech Cap Llc (Trc) holds 0% of its portfolio in UMH Properties, Inc. (NYSE:UMH) for 1,864 shares.

The stock decreased 2.40% or $0.31 during the last trading session, reaching $12.59. About 49,218 shares traded. UMH Properties, Inc. (NYSE:UMH) has risen 71.87% since March 19, 2017 and is uptrending. It has outperformed by 55.17% the S&P500.

Since February 15, 2018, it had 1 insider purchase, and 0 insider sales for $1,000 activity. QUIGLEY KENNETH K JR also bought $1,000 worth of UMH Properties, Inc. (NYSE:UMH) shares.

Analysts await UMH Properties, Inc. (NYSE:UMH) to report earnings on May, 8. They expect $0.18 earnings per share, up 5.88% or $0.01 from last year’s $0.17 per share. UMH’s profit will be $6.49M for 17.49 P/E if the $0.18 EPS becomes a reality. After $0.19 actual earnings per share reported by UMH Properties, Inc. for the previous quarter, Wall Street now forecasts -5.26% negative EPS growth.